Wells Fargo & Company Begins Coverage on Metsera (NASDAQ:MTSR)

Analysts at Wells Fargo & Company started coverage on shares of Metsera (NASDAQ:MTSR - Get Free Report) in a research note issued to investors on Friday, Marketbeat.com reports. The firm set an "overweight" rating and a $65.00 price target on the stock. Wells Fargo & Company's target price would indicate a potential upside of 124.14% from the stock's current price.

MTSR has been the topic of a number of other research reports. Evercore ISI initiated coverage on Metsera in a report on Tuesday, February 25th. They set an "outperform" rating on the stock. Guggenheim boosted their target price on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock. Finally, Bank of America began coverage on Metsera in a report on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $55.00.

Metsera Trading Down 2.0%

Shares of MTSR traded down $0.60 during mid-day trading on Friday, reaching $29.00. 1,021,717 shares of the company's stock traded hands, compared to its average volume of 977,849. The firm's 50-day simple moving average is $25.91. Metsera has a 12 month low of $12.30 and a 12 month high of $37.99.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Institutional Investors Weigh In On Metsera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in Metsera in the first quarter worth approximately $76,000. New York State Common Retirement Fund acquired a new position in Metsera in the first quarter worth approximately $131,000. Corebridge Financial Inc. acquired a new position in Metsera in the first quarter worth approximately $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Metsera in the first quarter worth approximately $248,000. Finally, MetLife Investment Management LLC acquired a new position in Metsera in the first quarter worth approximately $254,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.